• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bank Of America, Morgan Stanley And Other 3 Stocks To Watch Heading Into Tuesday

    7/16/24 3:08:43 AM ET
    $BAC
    $FBK
    $KYTX
    $MS
    Major Banks
    Finance
    Major Banks
    Finance
    Get the next $BAC alert in real time by email

    With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:

    • Wall Street expects Bank of America Corporation (NYSE:BAC) to report quarterly earnings at 80 cents per share on revenue of $25.22 billion before the opening bell. Bank of America shares gained 0.1% to $41.94 in after-hours trading.
    • FB Financial Corporation (NYSE:FBK) posted better-than-expected results for its second quarter on Monday. FB Financial shares rose 0.5% to $43.03 in the after-hours trading session.
    • Analysts are expecting Morgan Stanley (NYSE:MS) to post quarterly earnings at $1.65 per share on revenue of $14.3 billion. The company will release earnings before the markets open. Morgan Stanley shares rose 0.8% to $106.14 in after-hours trading.

    Check out our premarket coverage here

    • Kyverna Therapeutics, Inc. (NASDAQ:KYTX) shares rose sharply in after-hours trading on Monday after the company announced it received FDA Regenerative Medicine Advanced Therapy designation for KYV-101 in the treatment of patients with refractory stiff-person syndrome. Kyverna Therapeutics shares surged 7.5% to $10.65 in the after-hours trading session.
    • Analysts expect UnitedHealth Group Incorporated (NYSE:UNH) to post quarterly earnings at $6.66 per share on revenue of $98.84 billion after the closing bell. UnitedHealth shares rose 0.9% to $519.99 in after-hours trading.

    Check This Out:

    • Over $18M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying
    Get the next $BAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAC
    $FBK
    $KYTX
    $MS

    CompanyDatePrice TargetRatingAnalyst
    UnitedHealth Group Incorporated
    $UNH
    4/7/2026$300.00Reduce → Hold
    HSBC Securities
    Morgan Stanley
    $MS
    4/7/2026$196.00Neutral → Buy
    UBS
    FB Financial Corporation
    $FBK
    4/7/2026$62.00Mkt Perform → Strong Buy
    Raymond James
    FB Financial Corporation
    $FBK
    4/3/2026$65.00Neutral → Overweight
    Piper Sandler
    FB Financial Corporation
    $FBK
    4/2/2026$65.00Neutral → Overweight
    Piper Sandler
    UnitedHealth Group Incorporated
    $UNH
    4/1/2026$330.00Mkt Perform → Outperform
    Raymond James
    Bank of America Corporation
    $BAC
    4/1/2026$57.00Hold → Buy
    HSBC Securities
    Bank of America Corporation
    $BAC
    3/26/2026Buy
    Jefferies
    More analyst ratings

    $BAC
    $FBK
    $KYTX
    $MS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bank Of America Corp /De/ bought $4,303 worth of shares (343 units at $12.55) and sold $4,202 worth of shares (343 units at $12.25) (SEC Form 4)

    4 - BANK OF AMERICA CORP /DE/ (0000070858) (Reporting)

    1/28/26 1:23:38 PM ET
    $BAC
    Major Banks
    Finance

    Large owner Bank Of America Corp /De/ bought $10,319 worth of shares (1,000 units at $10.32) and sold $10,540 worth of shares (1,000 units at $10.54) (SEC Form 4)

    4 - BANK OF AMERICA CORP /DE/ (0000070858) (Reporting)

    12/22/25 5:14:47 PM ET
    $BAC
    Major Banks
    Finance

    Director Seidenberg Beth C bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:43:43 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BAC
    $FBK
    $KYTX
    $MS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UnitedHealth upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded UnitedHealth from Reduce to Hold and set a new price target of $300.00

    4/7/26 8:51:26 AM ET
    $UNH
    Medical Specialities
    Health Care

    Morgan Stanley upgraded by UBS with a new price target

    UBS upgraded Morgan Stanley from Neutral to Buy and set a new price target of $196.00

    4/7/26 8:36:03 AM ET
    $MS
    Investment Bankers/Brokers/Service
    Finance

    FB Financial upgraded by Raymond James with a new price target

    Raymond James upgraded FB Financial from Mkt Perform to Strong Buy and set a new price target of $62.00

    4/7/26 8:35:32 AM ET
    $FBK
    Major Banks
    Finance

    $BAC
    $FBK
    $KYTX
    $MS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Simkowitz Daniel A

    4 - MORGAN STANLEY (0000895421) (Issuer)

    4/17/26 4:41:18 PM ET
    $MS
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 4 filed by Saperstein Andrew M

    4 - MORGAN STANLEY (0000895421) (Issuer)

    4/17/26 4:38:02 PM ET
    $MS
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 4 filed by Yeshaya Sharon

    4 - MORGAN STANLEY (0000895421) (Issuer)

    4/17/26 4:37:32 PM ET
    $MS
    Investment Bankers/Brokers/Service
    Finance

    $BAC
    $FBK
    $KYTX
    $MS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

    100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial  Totality of efficacy and safety data reinforces miv-cel's differentiated and potential best-in-class profile for delivering durable, drug-free, disease-free remission with a single dose Company to host conference call on Wednesday, April 22, 2026, at 7:00 am ET EMERYVILLE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive longer-term follow-up data from the Phase 2 por

    4/20/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bank of America Declares Preferred Stock Dividends Payable in May and June 2026

    CHARLOTTE, N.C., April 17, 2026 /PRNewswire/ -- Bank of America Corporation today announced the Board of Directors has authorized regular cash dividends on the outstanding shares or depositary shares of the following series of preferred stock:  Series of Preferred StockDividend per Share or Depositary Share1Record DatePayment DateFloating Rate Non-Cumulative Preferred Stock, Series E$0.26355April 30May 15Floating Rate Non-Cumulative Preferred Stock, Series F$1,107.99178May 29June 15Adjustable Rate Non-Cumulative Preferred Stock, Series G$1,107.99178May 29June 15Floating Rate Non

    4/17/26 4:15:00 PM ET
    $BAC
    Major Banks
    Finance

    Eaton Vance Limited Duration Income Fund, Eaton Vance Senior Floating-Rate Trust, and Eaton Vance Senior Income Trust Announce Tender Offers for Outstanding Auction Preferred Shares

    Eaton Vance Limited Duration Income Fund (NYSE:EVV), Eaton Vance Senior Floating-Rate Trust (NYSE:EFR), and Eaton Vance Senior Income Trust (NYSE:EVF) (each a "Fund," and together, the "Funds") announced that the Board of Trustees of each Fund has authorized each Fund to conduct a voluntary tender offer for up to 100% of its outstanding auction preferred shares ("APS") at a price per share equal to 98% of the APS liquidation preference of $25,000 per share (or $24,500 per share), plus any unpaid APS dividends accrued through the expiration date of the tender offer. Each Fund's tender offer is expected to commence on or about April 30, 2026 and terminate on or about May 29, 2026, unless exte

    4/17/26 4:00:00 PM ET
    $EFR
    $EVF
    $EVV
    Trusts Except Educational Religious and Charitable
    Finance
    Investment Bankers/Brokers/Service
    Finance/Investors Services

    $BAC
    $FBK
    $KYTX
    $MS
    SEC Filings

    View All

    Kyverna Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)

    4/20/26 8:00:17 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form FWP filed by Morgan Stanley

    FWP - MORGAN STANLEY (0000895421) (Subject)

    4/17/26 5:13:06 PM ET
    $MS
    Investment Bankers/Brokers/Service
    Finance

    SEC Form FWP filed by Morgan Stanley

    FWP - MORGAN STANLEY (0000895421) (Subject)

    4/17/26 5:11:15 PM ET
    $MS
    Investment Bankers/Brokers/Service
    Finance

    $BAC
    $FBK
    $KYTX
    $MS
    Leadership Updates

    Live Leadership Updates

    View All

    Morgan Stanley Investment Management Enters Digital Investments Universe With Launch of Morgan Stanley Bitcoin Trust

    Morgan Stanley Investment Management (MSIM) announced today the launch of Morgan Stanley Bitcoin Trust (NYSE:MSBT), an exchange-traded product (ETP) that seeks to track the performance of bitcoin. MSIM is the first U.S. bank-affiliated asset manager to offer a cryptocurrency ETP, and reflects a continued, firmwide focus by Morgan Stanley to develop digital asset solutions designed to meet evolving client demand. "We are proud to introduce MSBT to the marketplace and believe this new ETP aligns with long-term trends in financial innovation and serves to strengthen the range of investments we provide investors," said Ben Huneke, Head of Morgan Stanley Investment Management. "MSBT is an ex

    4/8/26 8:25:00 AM ET
    $MS
    Investment Bankers/Brokers/Service
    Finance

    Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

    Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval experience to support Kyverna's next phase of growth EMERYVILLE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointments of Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors. Mr. Emany will assume the role of Audit Committee Chair, following the transition of Dan Spiegelman from this position, who has stepped d

    2/24/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

    EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Mayo Pujols as its Chief Technology Officer (CTO), effective February 9, 2026. Mr. Pujols brings more than 30 years of technical operations experience to the role with a deep background in leading late-stage and commercial manufacturing for cell and gene therapies. His work spans both large-scale and smaller biopharmaceutical companies with a proven track record of successfully advancing programs across their lifecycles. He succeeds Karen Walker, who is

    2/3/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BAC
    $FBK
    $KYTX
    $MS
    Financials

    Live finance-specific insights

    View All

    Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

    100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial  Totality of efficacy and safety data reinforces miv-cel's differentiated and potential best-in-class profile for delivering durable, drug-free, disease-free remission with a single dose Company to host conference call on Wednesday, April 22, 2026, at 7:00 am ET EMERYVILLE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive longer-term follow-up data from the Phase 2 por

    4/20/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bank of America Declares Preferred Stock Dividends Payable in May and June 2026

    CHARLOTTE, N.C., April 17, 2026 /PRNewswire/ -- Bank of America Corporation today announced the Board of Directors has authorized regular cash dividends on the outstanding shares or depositary shares of the following series of preferred stock:  Series of Preferred StockDividend per Share or Depositary Share1Record DatePayment DateFloating Rate Non-Cumulative Preferred Stock, Series E$0.26355April 30May 15Floating Rate Non-Cumulative Preferred Stock, Series F$1,107.99178May 29June 15Adjustable Rate Non-Cumulative Preferred Stock, Series G$1,107.99178May 29June 15Floating Rate Non

    4/17/26 4:15:00 PM ET
    $BAC
    Major Banks
    Finance

    Eaton Vance Limited Duration Income Fund, Eaton Vance Senior Floating-Rate Trust, and Eaton Vance Senior Income Trust Announce Tender Offers for Outstanding Auction Preferred Shares

    Eaton Vance Limited Duration Income Fund (NYSE:EVV), Eaton Vance Senior Floating-Rate Trust (NYSE:EFR), and Eaton Vance Senior Income Trust (NYSE:EVF) (each a "Fund," and together, the "Funds") announced that the Board of Trustees of each Fund has authorized each Fund to conduct a voluntary tender offer for up to 100% of its outstanding auction preferred shares ("APS") at a price per share equal to 98% of the APS liquidation preference of $25,000 per share (or $24,500 per share), plus any unpaid APS dividends accrued through the expiration date of the tender offer. Each Fund's tender offer is expected to commence on or about April 30, 2026 and terminate on or about May 29, 2026, unless exte

    4/17/26 4:00:00 PM ET
    $EFR
    $EVF
    $EVV
    Trusts Except Educational Religious and Charitable
    Finance
    Investment Bankers/Brokers/Service
    Finance/Investors Services

    $BAC
    $FBK
    $KYTX
    $MS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Bank of America Corporation

    SC 13D/A - BANK OF AMERICA CORP /DE/ (0000070858) (Filed by)

    12/13/24 4:29:10 PM ET
    $BAC
    Major Banks
    Finance

    Amendment: SEC Form SC 13G/A filed by FB Financial Corporation

    SC 13G/A - FB Financial Corp (0001649749) (Subject)

    11/14/24 1:28:34 PM ET
    $FBK
    Major Banks
    Finance

    SEC Form SC 13G filed by Kyverna Therapeutics Inc.

    SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)

    11/12/24 7:23:31 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care